Companies · Pharmaceuticals

Galecto, Inc.

Boston · Pharmaceuticals

Diligence memoA one-page analyst read on Galecto, Inc. — recommendation, valuation, rhythm, risks.
$428.3M
Total raised · real
3
Rounds
4.4×
Latest step-up
Top 2%
Sector rank · raised
Series D+
Latest stage · inferred · Wed Nov 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Galecto, Inc. looks over-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.27× the median modeled value of Series D+ Pharmaceuticals companies in 2025–2027 (7 peers) — value vs value, same stage and era.
Active
  • Last raise 8 mo ago; this sector typically re-raises about every 13 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Galecto, Inc. is one of 1610 Pharmaceuticals companies tracked from Boston. By capital raised it ranks among the largest (ahead of 99% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
48
Investors (latest)
2025-11-12
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries C · 2019-12-31 Raised $79M (real) Modeled valuation $2.8B (est)$79M$2.8BSeries C2019Series C · 2020-09-25 Raised $64M (real) Modeled valuation $2.1B (est)$64M$2.1BSeries C2020Series D+ · 2025-11-12 Raised $285M (real) Modeled valuation $2.0B (est)$285M$2.0BSeries D+2025+$64M+$285MCumulative $428M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series C$79.1M · 2019
Series C extension$64.2M · 2020
Series D+$285.0M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$2.0B
Base estimate est.
$1.4B
Conservative case
$2.4B
Upside case
$2.4B
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series C · modeled $2.8B · 2019-12-312019Series C · modeled $2.1B · 2020-09-25Series D+ · modeled $2.0B · 2025-11-122025
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
71%
Survival probability
57% low · 79% high
1.35×/yr
Annual markup
1.51×/yr upside case
0.6 yr
Elapsed time used
0.6 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
35 mo
Avg between rounds
$73.0M/yr
Capital velocity
6.5 yr
On record since
2019
First round
3
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 53× above median
This company$428.3M
Sector median$8.1M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 2.5× above median
This company$285.0M
Sector median$111.8M
Modeled value — vs sector median (estimate, all stages) 27× above median
This company$2.0B
Sector median$76.1M

Raised more than 99% of sector peers (real $). Modeled value above 94% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #2 of 7.

This companyCohort peer
$100.0M$1.0B$10.0B$100.0M$1.0BCapital raised (log)DBV Technologies S.A. · Series D+ Raised $306.9M · modeled $2.6B (est)NovaBay Pharmaceuticals, Inc. · Series D+ Raised $218.1M · modeled $912.5M (est)Pelage Pharmaceuticals, Inc. · Series D+ Raised $150.7M · modeled $900.8M (est)Triana Biomedicines, Inc. · Series D+ Raised $178.6M · modeled $852.1M (est)Quoin Pharmaceuticals, Ltd. · Series D+ Raised $113.8M · modeled $773.6M (est)Lexicon Pharmaceuticals, Inc. · Series D+ Raised $446.0M · modeled $373.9M (est)Galecto, Inc. (this company) Raised $428.3M · modeled $2.0B (est)Galecto, Inc.
CompanyStageRaised · realValue · estvs peer med.
DBV Technologies S.A.Series D+$306.9M$2.6B2.92×
Galecto, Inc. this companySeries D+$428.3M$2.0B2.27×
NovaBay Pharmaceuticals, Inc.Series D+$218.1M$912.5M1.01×
Pelage Pharmaceuticals, Inc.Series D+$150.7M$900.8M1.00×
Triana Biomedicines, Inc.Series D+$178.6M$852.1M0.95×
Quoin Pharmaceuticals, Ltd.Series D+$113.8M$773.6M0.86×
Lexicon Pharmaceuticals, Inc.Series D+$446.0M$373.9M0.42×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series C$79.1M2019-12-31$527.6M$2.8B90%
Series C$64.2M2020-09-25$428.0M$2.1B90%
Series D+$285.0M2025-11-12$2.4B$2.0B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series C$79.1M2019-12-31
    • First recorded raise — entered as Series C.
    • 35 investors on this round.
  2. Series C$64.2M2020-09-25
    • Raised 9 mo later, in step with the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 42 investors on this round.
  3. Series D+$285.0M2025-11-12
    • Raised again after 62 mo — slower than the ~13 mo sector norm.
    • Round 4.4× larger than the prior — scaling up.
    • 48 investors on this round.
Intelligence
2028 ~Q4
Modeled next raise · ~35mo cadence
$855.0M
Modeled next size est.range $555.8M$1.4B
4.4×
Last step-up
$73.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Karen Wagner1 other2020-09
Amit Q. Munshi2020-09
Amit T. Munshi2025-11
Carl Q. Goldfischer2020-09
Carl T. Goldfischer2025-11
Chandra Q. Leo2020-09
Chao Q. Khuong2020-09
Christopher T. Cain2025-11
David Q. Shapiro2020-09
Erez Q. Chimovits2020-09
Garrett T. Winslow2025-11
Hans Schambye2019-12
Hans T. Schambye2025-11
Jakob Dynnes Hansen2019-12
Jayson T. Dallas2025-11
Jon Freve2020-09
Julianne T. Bruno2025-11
Lori T. Firmani2025-11
Peter T. Harwin2025-11
Soren Q. Lemonius2020-09
Soren Q. Moller2020-09
Stephan Q. Christgau2020-09
Registry & provenance

Galecto, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1800315
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Lexicon Pharmaceuticals, Inc.PharmaceuticalsSeries D+$446.0M$373.9Msame sector · same stage
ADARx Pharmaceuticals, Inc.PharmaceuticalsSeries D+$352.5M$2.8Bsame sector · same stage
Catabasis Pharmaceuticals IncPharmaceuticalsSeries D+$349.6M$3.3Bsame sector · same stage
Olema Pharmaceuticals, Inc.PharmaceuticalsSeries D+$527.4M$2.4Bsame sector · same stage
Harmony Biosciences II, Inc.PharmaceuticalsSeries D+$345.0M$1.8Bsame sector · same stage
Bothwell Capital Holdings CorpPharmaceuticalsSeries D+$310.0M$1.8Bsame sector · same stage
DBV Technologies S.A.PharmaceuticalsSeries D+$306.9M$2.6Bsame sector · same stage
Precigen, Inc.PharmaceuticalsSeries D+$624.0M$405.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Galectin Therapeutics IncPharmaceuticalsSeed$114.1M89%
Galera Therapeutics, Inc.PharmaceuticalsSeries C$21.2M85%
Lipidio Pharmaceuticals Inc.PharmaceuticalsSeries A$143.2M81%
Balto Pharmaceuticals, Inc.PharmaceuticalsSeed$14.9M81%
Solaxa Inc.PharmaceuticalsPre-Seed$1.3M80%
Lexicon Pharmaceuticals, Inc.PharmaceuticalsSeries D+$373.9M80%
Cutispharma Holdings, Inc.PharmaceuticalsSeries C$2.5B80%
Amplyx Pharmaceuticals, Inc.PharmaceuticalsSeries C$3.2B79%
Frequently asked
How much funding has Galecto, Inc. raised?
Galecto, Inc. has raised approximately $428.3M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Galecto, Inc.'s estimated valuation?
Provath's modeled valuation for Galecto, Inc. is approximately $2.0B (modeled range $1.4B–$2.4B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Galecto, Inc. at?
Galecto, Inc.'s latest modeled financing stage is Series D+. Its most recent recorded round closed around Wed Nov 12.
What does Galecto, Inc. do and where is it based?
Galecto, Inc. operates in the Pharmaceuticals sector, based in Boston.
Explore related

See where Galecto, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Galecto, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.